We are live on
!
Find out more
Voloridge Investment Management Portfolio holdings
AUM
$25B
1-Year Est. Return
28.08%
This Fund
S&P 500
This Quarter
Est. Return
+6.27%
1 Year Est. Return
+28.08%
3 Year Est. Return
+85.2%
5 Year Est. Return
+73.43%
10 Year Est. Return
+582.16%
AUM
$17.9B
AUM Growth
-$597M
(-3.2%)
Cap. Flow
-$1.32B
Cap. Flow
% of AUM
-7.36%
Top 10 Holdings %
Top 10 Hldgs %
8.81%
Holding
1,709
New
345
Increased
450
Reduced
603
Closed
311
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$146M |
| 2 |
Apple
AAPL
|
+$129M |
| 3 |
Tesla
TSLA
|
+$110M |
| 4 |
Medtronic
MDT
|
+$104M |
| 5 |
Verizon
VZ
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$181M |
| 2 |
Microsoft
MSFT
|
+$177M |
| 3 |
Comcast
CMCSA
|
+$173M |
| 4 |
Adobe
ADBE
|
+$163M |
| 5 |
Broadcom
AVGO
|
+$157M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.34% |
| 2 | Healthcare | 14.31% |
| 3 | Consumer Discretionary | 12.9% |
| 4 | Industrials | 11.52% |
| 5 | Financials | 10.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
Neurocrine Biosciences
NBIX
$15.9B
| $4.26M | 0.02% |
+35,627
| New | +$4.17M |
|
702
NeoGenomics
NEO
$2.11B
| $4.25M | 0.02% |
460,290
-203,592
| -31% | -$1.9M |
|
|
GOOS
703
Canada Goose Holdings
GOOS
$844M
| $4.24M | 0.02% |
238,168
+126,627
| +114% | +$2.22M |
|
|
ESPR
704
DELISTED
Esperion Therapeutics
ESPR
| $4.23M | 0.02% |
+679,530
| New | +$4.86M |
|
705
Xerox
XRX
$412M
| $4.23M | 0.02% |
289,851
+153,199
| +112% | +$2.31M |
|
706
Hayward Holdings
HAYW
$3.25B
| $4.23M | 0.02% |
449,788
-88,833
| -16% | -$825K |
|
707
OneMain Financial
OMF
$7.44B
| $4.2M | 0.02% |
126,194
-387,010
| -75% | -$13.7M |
|
708
Wynn Resorts
WYNN
$10.6B
| $4.2M | 0.02% |
50,931
-47,706
| -48% | -$3.49M |
|
|
STOR
709
DELISTED
STORE Capital Corporation
STOR
| $4.2M | 0.02% |
130,891
-354,637
| -73% | -$11.3M |
|
|
MFA
710
MFA Financial
MFA
$925M
| $4.17M | 0.02% |
422,890
-236,089
| -36% | -$2.37M |
|
711
Constellium
CSTM
$4B
| $4.15M | 0.02% |
351,119
+75,858
| +28% | +$886K |
|
712
Axsome Therapeutics
AXSM
$11.2B
| $4.14M | 0.02% |
53,680
-160,113
| -75% | -$9.57M |
|
713
ICL Group
ICL
$7.06B
| $4.12M | 0.02% |
563,953
+27,863
| +5% | +$231K |
|
714
Triumph Financial Inc
TFIN
$1.83B
| $4.12M | 0.02% |
84,318
+1,372
| +2% | +$74.1K |
|
715
Rogers Communications
RCI
$19.4B
| $4.11M | 0.02% |
87,703
-106,320
| -55% | -$4.53M |
|
|
SFBS
716
ServisFirst Bancshares
SFBS
$4.95B
| $4.1M | 0.02% |
59,553
+27,289
| +85% | +$2.04M |
|
717
Credit Acceptance
CACC
$5.99B
| $4.1M | 0.02% |
+8,634
| New | +$3.96M |
|
718
BancFirst
BANF
$3.84B
| $4.09M | 0.02% |
46,414
-12,505
| -21% | -$1.18M |
|
719
MarineMax
HZO
$1.15B
| $4.09M | 0.02% |
131,051
-30,005
| -19% | -$943K |
|
720
Phreesia
PHR
$758M
| $4.08M | 0.02% |
126,028
-63,426
| -33% | -$1.72M |
|
|
B
721
Barrick Mining
B
$67.9B
| $4.07M | 0.02% |
236,868
-809,887
| -77% | -$12.9M |
|
|
INBX
722
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $4.07M | 0.02% |
+165,072
| New | +$4.85M |
|
723
HEICO Corp Class A
HEI.A
$38B
| $4.06M | 0.02% |
33,911
+284
| +0.8% | +$34.7K |
|
724
Bank of Hawaii
BOH
$3.13B
| $4.06M | 0.02% |
52,295
-21,465
| -29% | -$1.66M |
|
725
Canadian Imperial Bank of Commerce
CM
$110B
| $4.05M | 0.02% |
100,240
+55,634
| +125% | +$2.45M |
|
Similar funds
VAI
Voloridge Investment Management's Q4 2022 Portfolio in Review
As of Q4 2022, Voloridge Investment Management held 1,709 positions worth $17.9B, down 3.2% from $18.5B the previous quarter. Its ten largest holdings account for 8.8% of the portfolio.
Voloridge Investment Management withdrew a net $1.32B in Q4 2022, closing 311 positions and reducing 603 holdings. Its most notable exit was Berkshire Hathaway Class B, an estimated $181M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Voloridge Investment Management opened a new position in Edwards Lifesciences worth $142M.
- Voloridge Investment Management's largest Q4 2022 buy was Edwards Lifesciences: 1,898,822 shares worth $142M.
- Voloridge Investment Management added most to Tesla in Q4 2022, an estimated $110M increase.
- Voloridge Investment Management's biggest Q4 2022 reduction was Microsoft, cutting an estimated $177M.
- Voloridge Investment Management fully exited Berkshire Hathaway Class B in Q4 2022, selling an estimated $181M.
- Voloridge Investment Management's ten largest holdings make up 8.8% of its $17.9B portfolio in Q4 2022.
- Voloridge Investment Management opened 345 new positions and closed 311 in Q4 2022.
- Voloridge Investment Management's portfolio value fell 3.2% quarter-over-quarter to $17.9B.
Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.